文献速递神经核医学核素与放射性配体治疗

脑膜瘤诊疗一体化:生长抑素受体PET/CT显像与肽受体放射性核素治疗的回顾性分析

Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-17

单中心回顾性研究纳入152例患者共171个生长抑素受体(SSTR)表达阳性的脑膜瘤,比较[68Ga]Ga-DOTATOC、[68Ga]Ga-DOTATATE与[18F]AlF-NOTA-octreotide三种示踪剂的PET/CT定量表现,并分析12例接受肽受体放射性核素治疗(PRRT)的脑膜瘤患者的疗效。三种示踪剂均显示高肿瘤-本底对比,未见显著组间差异;PRRT疾病控制率为50%,中位无进展生存期8个月,总生存期20个月。

要点

  • SSTR PET/CT对脑膜瘤呈高对比显像,[18F]AlF-NOTA-octreotide似可与镓-68示踪剂临床互换。
  • 非相关指征显像中偶然发现脑膜瘤的比例为3.7%。
  • PRRT在经重度治疗的脑膜瘤患者中疾病控制率为50%。

核心结论

  • SSTR PET/CT可实现脑膜瘤高对比显像,[18F]AlF-NOTA-octreotide似可与镓-68标记示踪剂临床互换并具后勤优势。
  • PRRT在脑膜瘤中实现有意义的疾病稳定,支持在前瞻性随机研究中进一步验证。

研究设计与样本

  • 单中心回顾性研究纳入2007—2024年所有脑膜瘤患者的SSTR PET/CT扫描,示踪剂为[68Ga]Ga-DOTATOC、[68Ga]Ga-DOTATATE或[18F]AlF-NOTA-octreotide。
  • 对≥1 cm3的病灶采用三种勾画方法定量肿瘤摄取:绝对SUV阈值2.3、脑膜参考区SUVpeak的1.73倍相对阈值、病灶SUVmax的11%相对阈值,并计算肿瘤-本底比值。
  • 从机构登记库(2016—2024年)识别接受PRRT治疗的脑膜瘤患者。

主要发现

  • 4136次SSTR PET/CT中纳入152例患者共171个SSTR表达阳性的脑膜瘤。
  • 非相关指征显像中偶然发现脑膜瘤的比例为3.7%。
  • 对86个≥1 cm3病灶的定量分析显示[18F]AlF-NOTA-octreotide(n=7)、[68Ga]Ga-DOTATATE(n=73)和[68Ga]Ga-DOTATOC(n=6)摄取均稳健,各勾画策略下示踪剂间无显著差异。
  • 所有示踪剂均显示高肿瘤-脑膜摄取比值:[18F]AlF-NOTA-octreotide为51—146,[68Ga]Ga-DOTATATE为10—329,[68Ga]Ga-DOTATOC为12—76。
  • 12例经重度治疗的PRRT患者中,疾病控制率为50%,中位无进展生存期8个月,总生存期20个月。

关键数值与推荐

  • 病灶≥1 cm3时采用三种勾画方法定量:绝对SUV阈值2.3、脑膜参考区SUVpeak的1.73倍相对阈值、病灶SUVmax的11%相对阈值。
  • PRRT疗效评价指标:疾病控制率50%,中位无进展生存期8个月,中位总生存期20个月。

临床怎么用

  • SSTR PET/CT可用于脑膜瘤的高对比显像,[18F]AlF-NOTA-octreotide因后勤优势可考虑替代镓-68标记示踪剂。
  • 对SSTR PET/CT偶然发现的脑膜瘤(占非相关指征显像的3.7%)应结合临床进一步评估。
  • PRRT可作为经重度治疗脑膜瘤患者的治疗选择之一,但需在前瞻性随机研究中进一步验证。

局限性

  • 本研究为单中心回顾性设计。
  • PRRT分析样本量小(12例),且患者均经重度治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to evaluate differences in PET/CT imaging of meningioma using both gallium-68- and fluorine-18-labelled somatostatin receptor (SSTR) tracers, to characterize incidentally detected meningiomas on SSTR PET/CT, and to analyse institutional experience with Peptide Receptor Radionuclide Therapy (PRRT) in meningioma. METHODS: This single centre retrospective study included all SSTR PET/CT scans of meningioma patients (2007-2024) performed with [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE or [18F]AlF-NOTA-octreotide. For lesions ≥ 1cm3, tumour uptake was quantified using three distinct delineation methods: an absolute SUV threshold of 2.3, a relative threshold of 1.73 × SUVpeak of a meningeal reference region, and a relative threshold of 11% of the lesion's SUVmax. Tumour-to-background ratios were calculated. Meningioma patients treated with PRRT were identified from our institutional registry (2016-2024). RESULTS: Of 4,136 SSTR PET/CTs, 152 patients with 171 SSTR-expressing meningiomas were included. Incidental meningiomas were found in 3.7% of patients imaged for unrelated indications. Quantitative analysis of 86 lesions (≥ 1 cm3) showed robust uptake for [18F]AlF-NOTA-octreotide (n = 7), [68Ga]Ga-DOTATATE (n = 73), and [68Ga]Ga-DOTATOC (n = 6), without significant between-tracer differences across delineation strategies. All tracers demonstrated high tumour-to-meningeal uptake ratios with ratios ranging from 51 to 146 for [18F]AlF-NOTA-octreotide, 10-329 for [68Ga]Ga-DOTATATE, and 12-76 for [68Ga]Ga-DOTATOC, confirming excellent tumour-to-background contrast. Among 12 heavily pretreated patients receiving PRRT, disease control rate was 50%, median progression-free survival 8 months, and overall survival 20 months. CONCLUSION: SSTR PET/CT enables high-contrast meningioma visualisation. [18F]AlF-NOTA-octreotide seems clinically interchangeable with gallium-68-labelled tracers, while offering logistical advantages. PRRT achieves meaningful disease stabilisation, supporting further validation in prospective randomised studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Degryse L, Teles L, De Vleeschouwer S, et al. Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41699279. doi:10.1007/s00259-026-07771-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。